Israel gynecology drugs market
is expected to show an impressive growth during the forecast period, 2024-2028. The Israel gynecology drugs market is expected
to boost due to factors such as increasing prevalence of gynecological
disorders, growing aging population, rising awareness among women's health,
technological advancements, and government initiatives. As women's healthcare
continues to gain importance, the demand for gynecology drugs is expected to
rise, leading to continued innovation and development in this field. The
lifestyle of women in Israel has reportedly undergone a significant change
leading to unhealthy lifestyle that increased the prevalence of gynecological
disorders impacting the reproductive system. Gynecological therapies have been
fueled in recent years by a sharp growth in the field of medical innovation for
the treatment of diseases related to gynecology to meet unmet healthcare
requirements.
Different
brands operating in Israel and manufacturing same generic gynecological
medications that are mostly prescribed have extremely significant price
differences in the country. The cost of the medication is crucial for long-term
adherence to the treatment and for effective drug therapy of any gynecological
condition or disease. This can be accomplished by altering governmental
policies and regulations, including focus on pharmacoeconomic and the benefits
of opting to more affordable treatments so that women can easily avail
medication.
Several
pharmaceutical companies are active in the market for gynecology drugs for the
development of novel gynecology treatments with advanced efficacy and low side
effects. This element is promoting market growth. The major players in the Israel
gynecology drugs market are becoming more interested in expanding their line of
products. They are intensifying product launch activities to accomplish this
goal. A few initiatives are supporting their delivery channels in the
background. All these initiatives point to a hopeful rise in the market for Israel
gynecology drugs.
Moreover,
Israel has a robust pharmaceutical industry and is home to several leading
companies that develop and manufacture gynecology drugs. Recent developments in
gynecology drugs have led to improved treatment options for women's health
issues. Non-hormonal treatments for menopausal symptoms, targeted therapies for
gynecological cancers, injectable contraceptives, vaginal microbiome therapies,
and personalized medicines are contributing to the growth of the Israel
gynecology drugs market.
Increasing
Prevalence of Gynecological Disorders
The incidence
of gynecological disorders such as endometriosis, polycystic ovary syndrome
(PCOS), and uterine fibroids is increasing in Israel. These disorders can cause
severe pain, infertility, and other complications that significantly impact the
quality of life of affected women. The rising incidence of these disorders is
driving the demand for gynecology drugs in Israel, which can provide relief
from symptoms and improve overall health outcomes. Moreover, PCOS is the most
common occurring disorder which is one of the most common factors contributing
to infertility among women and can only be treated by medication and healthy
lifestyle. Changes in lifestyle, such as a sedentary lifestyle, poor diet, and
stress, are also contributing to the increased risk of gynecological disorders.
The availability of improved diagnostic methods, such as ultrasound and MRI, is
also used regularly to detect gynecological disorders that may have gone
undiagnosed in the past. Thus, with the emergence of more gynecological diseases,
the demand for cost-effective drugs is also expected to rise in the country during
the forecast period.
Growing
Aging Population and Demand for Personalized Medicine
The
aging population is another key driver of the Israel gynecology drugs market.
As women age, they become more susceptible to gynecological disorders such as
menopause, osteoporosis, and breast cancer. According to a report published
by Permanent Mission of Israel, in 2018, 11.8% of Israel's population or
1,056,300 people were of 65 years and above, of whom 586,000 were women
(55.5%). The aging population is also more likely to require gynecological
surgery, which can further drive the demand for gynecology drugs for
post-operative pain management and reduce the risk of complications in the
country. Personalized medicines involve tailoring medical treatments to an
individual's specific genetic makeup, lifestyle, and environmental factors,
which is also in trend from the past few years. In gynecology, personalized
medicines can be used to identify women who are at increased risk of gynecological
cancers or who may be more likely to experience side effects from certain
drugs. This can help healthcare providers choose the most effective treatment
options for individual patients.
Rising
Awareness of Women's Health
The
growing awareness of women's health is another key driver of the gynecology
drugs market. Women are increasingly taking charge of their health and seeking
out treatments for gynecological disorders. This trend is driven by various
factors, including increased education, access to information, and the rise of
social media. Women are also more likely to discuss their health issues with
their healthcare providers, leading to earlier diagnosis and treatment of
gynecological disorders.
Moreover,
the availability of over-the-counter drugs in the country is increasing
awareness among women about their health and well-being. One notable Israel-based
company is OCON Medical, which develops and manufactures IUDs (intrauterine
devices) for contraception, as well as other medical devices for women's
health. Their flagship product, the Ballerine IUB, a copper-based IUD that is
designed to be more flexible and comfortable for women than traditional IUDs
has been extensively adopted in Israel as well as globally as one of the most
used gynecology drugs in the hormonal contraceptives category.
Another
Israeli company that is active in the Israel gynecology drugs market is Teva
Pharmaceuticals. Teva is one of the world's largest generic drug manufacturers
and has a range of products for women's health, including hormonal
contraceptives and treatments for menopausal symptoms.
In
addition to these companies, there are also several Israeli startups that are
developing innovative diagnostic systems for treatment and medication. For example,
InnoLap Surgical is developing a minimally invasive surgical device for the
treatment of uterine fibroids, while HeraMED is developing a connected
pregnancy monitoring platform that can help detect potential complications in
pregnancy and can be further treated by utilizing fetal medicines.
Many
gynecology drugs are used in over half of all pregnancies, and prevalence of
use is increasing with more awareness among the female population. The most
used drugs include antiemetics, antacids, antihistamines, analgesics,
antimicrobials, diuretics, hypnotics, tranquilizers, and others. There are many
other medications, such as Clotrimazole, which are commonly used for treating
infection and maintenance of women hygiene. Miconazole is another anti-fungal
agent which is prescribed for various skin infections and for vaginal yeast
infections. Thus, the Israel gynecology drugs market is expected to grow and
innovate in the coming years, with Israeli companies and startups playing a significant
role in advancing women's health in the country.
Targeted
Therapies for Gynecological Cancers are Expected to Drive the Israel Gynecology
Market
In the
recent years, there has been a rise in the rate of gynecological cancers such
as ovarian, cervical, and endometrial cancers which can be challenging to treat
if not diagnosed at an early stage. However, in recent years, targeted
therapies have been developed that can specifically target cancer cells,
leaving healthy cells unharmed. For instance, Poly
(ADP-ribose) polymerases (PARP) inhibitors have been approved for the treatment
of ovarian and breast cancers that have specific genetic mutations. These drugs
work by inhibiting the enzyme PARP, which is essential for repairing DNA damage
in cancer cells.
According
to a study in PubMed, women in Israel have significantly higher annual ASRs
(age-standardized rates) for ovarian, cervical, and uterine malignancies.
Cervical cancer strikes women at the later stage of life or after the onset of
menopause. In the Israeli population, the distribution of cancer stages for
uterine, ovarian, and cervical malignancies is comparable. Age-standardized
incidence of ovarian cancer among Israeli women decreased significantly over
the course of the study due to the availability of gynecological drugs in the
market for early treatment of the symptoms. Pre-invasive cervical disease
increased considerably at an age-standardized rate in older women. Advancements
in technology have also led to the development of new and innovative gynecology
drugs. The development of non-hormonal therapies for menopause symptoms has led
to increased demand for these drugs. Similarly, the development of targeted
therapies for gynecological cancers has led to improved survival rates and
better health outcomes for affected women.
Download Free Sample Report
Market Segmentation
The Israel
gynecology drugs market is segmented into therapeutics,
indication, distribution channel, regional distribution, and company. Based
on therapeutics, the Israel gynecology drugs market is fragmented into non-hormonal
therapy and hormonal therapy. Based on indication, the market is segmented into
contraception, gynecology infections, female infertility, postmenopausal
disorders, polycystic ovary syndrome, osteoporosis, gynecology cancer,
endometriosis, and others. By distribution channel, the Israel gynecology drugs
market can be segmented into retail pharmacies, hospital pharmacies, and online
pharmacies.
Market Players
Teva
Pharmaceutical Industries Ltd., Pfizer Inc. GlaxoSmithKline plc, AstraZeneca
Israel, Johnson & Johnson, Bayer Israel Ltd., Abbott Laboratories Ltd., Eli
Lilly Israel Ltd., AbbVie Inc., and OCON Medical are some of the leading
players operating in the Israel gynecology drugs market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historical Years
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report Coverage
|
Revenue forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments Covered
|
·
Therapeutics
·
Indication
·
Distribution Channel
|
|
Regional Scope
|
The
Mediterranean coastal plain, The Central Hills, The Jordan Rift Valley, and The
Negev Desert
|
|
Key Companies Profiled
|
Teva Pharmaceutical Industries Ltd.,
Pfizer Inc. GlaxoSmithKline plc, AstraZeneca Israel, Johnson & Johnson,
Bayer Israel Ltd., Abbott Laboratories Ltd., Eli Lilly Israel Ltd., AbbVie
Inc., and OCON Medical
|
|
Customization Scope
|
10% free report customization with purchase. Addition or
alteration to regional & segment scope.
|
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, the Israel gynecology
drugs market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
·
Israel Gynecology Drugs Market,
By Therapeutics:
- Non-Hormonal Therapy
- Hormonal Therapy
·
Israel Gynecology Drugs, By Indication:
o Contraception
o Gynecology
Infections
o Female
Infertility
o Postmenopausal
disorders
o Polycystic
Ovary Syndrome
o Osteoporosis
o Gynecology
Cancer
o Endometriosis
o Others
- Israel Gynecology Drugs Market, By Distribution
Channel:
- Retail Pharmacies
- Hospital
Pharmacies
- Online Pharmacies
- Israel Gynecology Drugs Market, By Region:
- The Mediterranean coastal plain
- The Central Hills
- The Jordan Rift Valley
- The Negev Desert West
Competitive
Landscape
Company Profiles: Detailed analysis of the major
companies present in the Israel gynecology drugs market.
Available
Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Israel Gynecology Drugs Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at [email protected]